Roche's Tecentriq hits a lung cancer slowdown in its bid to challenge Merck
admin 6th September 2018 Uncategorised 0Roche has been chomping at the bit to challenge Merck with its Tecentriq-plus-Avastin cocktail in previously untreated non-small cell lung cancer. But with the FDA delaying a decision on its combo approval, it’s going to have to wait.
More: Roche's Tecentriq hits a lung cancer slowdown in its bid to challenge Merck
Source: fierce